New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDS5 vs Larazotide Acetate

DS5 vs Larazotide Acetate

Side-by-side comparison of key properties, dosing, and research.

Sleep Optimization
DS5
Recovery & Repair
Larazotide Acetate
Summary
DS5 is a synthetic variant of the delta sleep-inducing peptide (DSIP), a nonapeptide originally isolated from rabbit cerebrospinal fluid during slow-wave sleep. Like DSIP, DS5 is explored for sleep optimization, stress modulation, and circadian rhythm normalization, with proposed improvements in potency or stability over the parent molecule.
Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
Half-Life
Estimated 30-60 minutes (peptide degradation)
Local gut action; minimal systemic exposure
Admin Route
Subcutaneous, Intranasal (research)
Oral
Research
Typical Dose
200-500 mcg per dose
0.5-2 mg
Frequency
Once nightly
3x daily
Key Benefits
  • Promotes delta-wave (deep) sleep and improves sleep quality
  • May reduce sleep onset latency
  • HPA axis modulation for stress reduction
  • Non-addictive sleep support without tolerance development
  • Potential circadian rhythm normalization
  • Explored for insomnia, chronic stress, and PTSD-related sleep disturbance
  • Directly reduces intestinal tight junction permeability
  • Clinical efficacy in celiac disease (Phase 3 trials)
  • Reduces systemic inflammation from gut permeability
  • Targets root cause of leaky gut (Zonulin pathway)
  • Local gut action without systemic absorption
  • Potential application in IBS, IBD, autoimmune conditions
Side Effects
  • Generally well-tolerated in research subjects
  • Possible morning grogginess at higher doses
  • Mild blood pressure fluctuations reported with DSIP
  • Limited human safety data for DS5 specifically
  • Headache (mild, dose-dependent)
  • Nausea (rare)
  • Well-tolerated overall in clinical trials
Stacks With